Navigation Links
Derma Sciences Reports Fourth Quarter Year-End Results for 2007
Date:4/1/2008

2006

Net Sales $10,651,944 $7,687,009

Cost of sales 7,231,758 5,041,739

Gross Profit 3,420,186 2,645,270

Operating expenses

Selling, general and administrative 3,968,259 2,399,899

Research and development 868,069 -

Goodwill impairment - 200,000

Total operating expenses 4,836,328 2,599,899

Operating (loss) income (1,416,142) 45,371

Other expense (income)

Interest expense 270,605 75,379

Loss on debt extinguishment 256,628 -

Other expense (income) 35,699 (21,950)

Total other expense 562,932 53,429

Loss before provision for income taxes (1,979,074) (8,058)

Provision for income taxes 66,869 99,341

Net Loss $(2,045,943) $(107,399)

Loss per common share - basic and diluted $(0.07) $0.00

Shares used in computing loss per common share

- basic and diluted 30,289,386 24,906,160

Consolidated Statements of Operations (Audited)

Year ended

December 31,

2007 2006

Net Sales $34,135,401 $27,887,391

Cost of sales 22,530,986 18,235,003

Gross Profit 11,604,415 9,652,388

Operating ex
'/>"/>

SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...its of switching to voice over Internet protocol (...at the Italian Community Center in Milwaukee. Near... users share their experiences with VoIP. , ,Clear...erry Rocco, Cisco Systems, and Pat Scheckel, VoIP ...Brian Carlson, manager network/communications for ...
...ence faculty at the University of Wisconsin-Eau Cl...h more opportunities to work on research relating ...e university to assist local industries. , ,UW-Eau...ll support research, facilitate collaboration amon...ractions between the university and local industri...
...Julius truly cares about me. He often sends me sto...as for how to buy prescription drugs on the cheap....duction. Ursula seems more interested in enlargeme...up in the From line of my e-mail every day, usuall...in the morning is cleaning out unsolicited message...
...roadcast Systems and Madison-based MyWeather LLC...tion that alerts for breaking news and severe weat...ated television stations. , ,Powered by MyWeather ...imely information to people while they are at work... Desktop Alert to proactively grab viewers attenti...
Other Biology Technology:VoIP: Are we there yet? 2UW-Eau Claire creates Materials Science Center 2UW-Eau Claire creates Materials Science Center 3Putting spam back in the can wont be all that easy 2
(Date:7/24/2008)...tate University College of Medicine, Hershey, Penn...uimod, a clinically important immune response modi... is dependent on the Opioid Growth Factor (OGF)-OG...very, reported in the August 08 issue of Experime...into a widely used drug that may lead to developme...
(Date:7/24/2008)... talk, they might tell potential suitors, "I like ...come slither look. But worms send their valentines...al code researchers are now cracking, according to...nal Nature . , Scientists from the University ...titute of Technology and the U.S. Department of Ag...
(Date:7/24/2008)...uced carbon storage in western U.S. forests , A...entury has caused a widespread increase in fire-in...stems growing on trees within western U.S. forests...re thought to account for much of North America,s ...ound biomass, Fellows and Goulden compare Californ...
(Date:7/23/2008)...together internationally renowned scientists from ...apan, Australia and India to address ancient micr...e are bringing together the world,s best scientist...izer J. William Schopf, founder and director of th...cs, Center for the Study of Evolution and the Orig...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 1Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 2Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 3Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 4Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 5Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 7Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 8Amylin Pharmaceuticals to Webcast Conference Call 5055 1Amylin Pharmaceuticals to Webcast Conference Call 5055 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 1Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 2
...s has,found the first clear evidence that the proc...ility to recognize and respond to a million,differ...f genes whose,only apparent function is to jump ar...ially cut themselves out of the genetic material, ...ght have been borrowed by cells,needing to build m...
...or of Research at the Molecular Sciences Institut... approach to simulation of intracellular,biochemic...Biotechnology.,The research article, entitled "Au...ith Moleculizer 1.0" (pdf) ,describes MSI,s discre...f the thousands of complex species formed from pat...
...em the rising rate of HIV infection, warn two seni...An estimated 38 million people worldwide, includin...IV, and a record 4.8 million became infected in 20...ncrease is socioeconomic, but the increase also re...s. , For instance, the search for a vaccine agains...
...al nervous system (CNS), where it influences neuro...an now use microarray technology to study brain fu...ed in the February issue of Alcoholism: Clinical &...alcohol on what is called "gene expression" in the... have exactly the same deoxyribonucleic acid (DNA)...
Other Biology News:Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3Alcohol's effects on gene expression in the central nervous system 2Alcohol's effects on gene expression in the central nervous system 3Alcohol's effects on gene expression in the central nervous system 4
The epitope recognized by A300-183A maps to the C-terminus of isoform 5 of human quaking homolog according to entry AAH19917.1 (GeneID 9444). The epitope is not found in isoforms 1, 2, 3, 4, 6, 7 or
... ml Dynabeads Epoxy (4.5 m). Hydrophobic naked be...deal for coupling of antibodies for cell applicati...ial coupling with covalent binding of primary amin...ring within 16-20 hours. Coupling reactions can be...
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details.
St. Louis encephalitis Immunogen: St. Louis encephalitis. Storage: -20 C, Avoid Freeze/Thaw Cycles
Biology Products: